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Sir,
We appreciate the comments and data provided by Santini et al
based upon our recent report (Overman et al, 2010; Figure 1). The
use of anti-EGFR therapy in small bowel adenocarcinoma (SBA) is
rationale, based upon the high-level expression of the target and
known activity of this agent in adenocarcinomas of the large
intestine. Though small and large intestinal adenocarcinomas
differ dramatically in incidence, a number of similarities in clinical
behaviour, such as metastatic site predilection and chemotherapy
responsiveness, do exist. As activating mutations in the Kras
oncogene are critical in determining the activity of anti-EGFR
therapy in colorectal cancer, molecular testing for mutations in the
Kras gene must also be incorporated into the assessment of anti-
EGFR therapy in SBA.
In the commentary by Santini et al, an impressive radiographic
response of 75% was observed in four patients treated with the
combination of cetuximab and irinotecan in a primarily Kras wild-
type SBA population. As mentioned by the authors, this finding
is encouraging and appears improved over the response rates
observed with 5-fluorouracil and irinotecan combinations (Zaanan
et al, 2010). However, the contributory effect of cetuximab cannot
be determined as cetuximab was combined with a known active
agent in SBA. We have recently treated a 67-year-old man with
metastatic moderately differentiated adenocarcinoma of the
duodenum to liver and retroperitoneal lymph nodes with single-
agent cetuximab (500mgm
2 every other week) as the fourth-line
therapy. After 8 weeks, a 24% reduction in tumour size per RECIST
criteria was observed. The pre-treatment (A) and post-treatment
(B) computed tomography images are shown in accompanying
figure. The subsequent treatment course was complicated by
cholangitis and radiographic progression occurred after 20 weeks.
We agree with Santini et al that further prospective studies are
needed to determine the role of anti-EGFR therapy in SBA. In an
attempt to build upon our previous work with the combination of
capecitabine and oxaliplatin, CAPOX (Overman et al, 2009), we are
currently initiating a phase II study evaluating the combination of
panitumumab with CAPOX as the first-line treatment for advanced
SBA with wild-type Kras.
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Figure 1 Pre-treatment (A) and post-treatment (B) computed tomography images showing radiographic response to single agent cetuximab in a patient
with metastatic duodenal adenocarcinoma.
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